Navigation Links
Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
Date:4/27/2012

ction. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website, www.ampiopharma.com.

Forward-Looking Statements
Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, successful commercialization and marketing of Zertane™ and the combination drug in Korea, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Contact: Investor Relations, Ampio Pharmaceuticals, Inc., 720-437-6500


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ampio Strengthens Patent Protection for Lead Drug Ampion™
2. Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
3. Champions Oncology Reports Fiscal 2012 Third Quarter Financial Results
4. Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
5. Ampio Pharmaceuticals Schedules 2012 Outlook Webcast
6. Executive Changes at Ampio
7. Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
8. Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million
9. Ampio Responds to Recent Publications by Anonymous Short Sellers
10. Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
11. FDA Advisory Panel Recommends Against Approval of Champion® Heart Failure Management System for Patients With Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... July 31, 2015 Magnaquest, ... video, data and cloud computing operators has signed ... pharma giant for Internet of Things (IoT) related ... offered on subscription model.      (Logo: ... is striving for business innovations to make healthcare ...
(Date:7/30/2015)... -- ResMed Inc. (NYSE: RMD ) today announced results ... the quarter was $453.1 million, a 9 percent increase ... 17 percent increase on a constant currency basis).  Net ... June 30, 2014.  Diluted earnings per share for the ... 30, 2014.  The results for the ...
(Date:7/30/2015)... BOTHELL, Wash. and VANCOUVER ... OGXI ) announced today that it will report ... 13, 2015. Company management will host a conference call ... provide an overview of financial results, clinical development programs ... access the webcast, log on to the Investor Relations ...
Breaking Medicine Technology:Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
... a privately held personalized medicine company focused on cancer, ... C (GCC) Lymph Nodes (LN) Classification as a Prognostic ... Pooled Analysis" at the 2012 American Society of Clinical ... 21, 2012.  The data from the paper demonstrate the ...
... 23, 2012 InspireMD, Inc. (OTC BB: NSPR) (the ... the development and commercialization of its proprietary stent platform ... today announced its business objectives for 2012 and reviewed ... the Company,s proprietary MicroNet™ platform technology. ...
Cached Medicine Technology:Signal Genetics Announces Publication of Meta-Analysis of its Colon Cancer Test-Previstage™ GCC Confirming Prognostic Capabilities in Patients with Colon Cancer 2InspireMD Provides Corporate Update, Plans for 2012 2InspireMD Provides Corporate Update, Plans for 2012 3InspireMD Provides Corporate Update, Plans for 2012 4InspireMD Provides Corporate Update, Plans for 2012 5InspireMD Provides Corporate Update, Plans for 2012 6
(Date:8/3/2015)... Miami, Florida (PRWEB) , ... August 03, 2015 , ... ... neuropathy pain accompanied by tissue injury caused by diabetes after many years of suffering ... work many times, and he didn’t want to ask for extra time off or ...
(Date:8/3/2015)... ... ... The American Institute of Architects (AIA) and ... a wide range of initiatives ranging from code development and compliance to sustainability ... membership, consisting of practicing design professionals, code officials, and the building industry representatives, ...
(Date:8/2/2015)... ... ... A new Phase I research study is looking at a vaccine that hopes ... G. Lucas, M.D. , chief of the division of pediatric hematology/oncology and stem cell ... Hospital and in the UofL Department of Pediatrics . Patients are currently ...
(Date:8/1/2015)... ... August 02, 2015 , ... AlignLife Office Coordinator Heather Pugh ... of care for patients at this natural health care center in Winamac. , "Oftentimes ... Heal said. "Heather's role is vital to our approach because we want to focus ...
(Date:8/1/2015)... ... August 01, 2015 , ... The condition where veins are ... and women often causing pain and discomfort. Those who spend a lot of time ... Northeast Houston Vein Center is doing what it can to create awareness and provide ...
Breaking Medicine News(10 mins):Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 3Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:New Patient Advocate Enhances Natural Health Care 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3
... ... expensive education in the thriving nursing industry. , ... Seattle, Washington (PRWEB) July 30, 2009 -- According to ... and online nursing degrees are becoming a popular and effective way to capitalize on ...
... with the autoimmune disease systemic lupus erythematosus (SLE) have ... in their immune responses and treatment with immunosuppressive drugs. ... in immunocompromised patients, it is recommended that patients with ... do not increase disease activity. Both antibody and cell-mediated ...
... , , TAMPA, Fla., July 29 ... great excitement and enthusiasm that Tampa Bay Radiation Oncology announces the grand ... 2009. Located at 12206 Bruce B Downs Blvd, near the VA ... to residents in the Tampa Bay area communities. , , ...
... , , ... a beautiful place for patients to relax, it is an award ... Agnes and Morland Hamilton Healing Conservatory at Aurora St. Luke,s Medical ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20090303/CG78204LOGO-b ) , ...
... OF PRUSSIA, Pa., July 29 Health Market Science ... product for the master data management market. The ... including life sciences, payer, pharmacy benefits management and pharmacy. ... for complete customer master data management. , ...
... , ADDISON, Texas, July 29, ULURU Inc. ... and best clinical practice will be demonstrated in a hands-on Wound Care ... August 2. In addition, clinical evidence on the treatment of wounds ... meeting. , , Renaat Van den Hooff, President and ...
Cached Medicine News:Health News:All Nursing Schools Sheds Light on Online Nursing Degree Opportunities in a Rough Economy 2Health News:Immune responses to flu vaccine are diminished in lupus patients 2Health News:Aurora St. Luke's Healing Garden Earns LEED Certification 2Health News:Health Market Science Unveils CompleteView, the Most Comprehensive Master Data Management (MDM) Solution Available in the Healthcare Market 2Health News:Health Market Science Unveils CompleteView, the Most Comprehensive Master Data Management (MDM) Solution Available in the Healthcare Market 3Health News:ULURU Inc. to Present Altrazeal(TM) Clinical Evidence at the American Podiatric Medical Association (APMA) Annual Scientific Meeting in Toronto, Canada 2Health News:ULURU Inc. to Present Altrazeal(TM) Clinical Evidence at the American Podiatric Medical Association (APMA) Annual Scientific Meeting in Toronto, Canada 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: